Anti-Postmenopausal osteoporosis effects of Isopsoralen: A bioinformatics-integrated experimental study

Phytother Res. 2023 Jan;37(1):231-251. doi: 10.1002/ptr.7609. Epub 2022 Sep 19.

Abstract

Isopsoralen (IPRN), which comes from the fruit of Psoralea corylifolia, has been identified as a kind of phytoestrogen and has been proven to be effective for the treatment of osteoporosis (OP). However, the mechanisms underlying IPRN's anti-OP effects, especially the anti-postmenopausal osteoporosis (PMOP) effects, remain indistinct. Thus, this study aimed to investigate the effects and mechanisms of IPRN's anti-PMOP activity. In this study, the bioinformatics results predicted that IPRN could resist PMOP by targeting EGFR, AKT1, SRC, CCND1, ESR1 (ER-α), AR, PGR, BRCA1, PTGS2, and IGF1R. An ovariectomized (OVX) mice model and a H2 O2 -induced bone marrow mesenchyml stem cells (BMSCs) model confirmed that IPRN could inhibit the bone loss induced by OVX in mice and promote the osteogenic differentiation in H2 O2 -induced BMSCs by inhibiting oxidative stress and apoptosis. Moreover, IPRN could significantly produce the above effects by upregulating ESR1. IPRN might be a therapeutic agent for PMOP by acting as an estrogen replacement agent and a natural antioxidant.

Keywords: Isopsoralen; bioinformatics; estrogen receptor; oxidative stress; phytoestrogens; postmenopausal osteoporosis.

MeSH terms

  • Animals
  • Cell Differentiation
  • Female
  • Humans
  • Mesenchymal Stem Cells*
  • Mice
  • Osteogenesis
  • Osteoporosis* / drug therapy
  • Osteoporosis, Postmenopausal* / drug therapy

Substances

  • angelicin